{"classes":[{"categories":[{"measurements":[{"comment":"SAS software does not compute a confidence interval when the estimate is 100%.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"groupId":"OG001","lowerLimit":"46.5","upperLimit":"95.0","value":"70.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.6","upperLimit":"88.8","value":"84.7"},{"groupId":"OG001","lowerLimit":"73.2","upperLimit":"82.7","value":"77.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"369"}],"units":"Participants"}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"98.6","value":"66.8"},{"groupId":"OG001","lowerLimit":"67.4","upperLimit":"100","value":"85.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"399"}],"units":"Participants"}],"description":"NIH-required analysis. An event for overall survival is death due to any cause. Survival time is defined as time from randomization to the date of death or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. The protocol endpoint is hazard ratio, which is reported in the statistical analysis results. Five-year rate is reported simply as summary data; it is not the outcome measure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible participants. Data were stratified by ethnicity.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Analysis was to occur after 180 deaths were reported. Analysis occurred after 133 deaths were reported. Maximum follow-up at time of analysis was 6.5 years.","title":"Overall Survival by Ethnicity","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}